

DAFTAR PUSTAKA

- [1] J. D. Murray, “Mathematical biology [electronic resource],” 2002.
- [2] M. Lindstrom *et al.*, “Global burden of cardiovascular diseases and risks collaboration, 1990-2021,” *J. Am. Coll. Cardiol.*, vol. 80, no. 25, pp. 2372–2425, 2022, doi: 10.1016/j.jacc.2022.11.001.
- [3] S. Przedborski, M. Vila, and V. Jackson-Lewis, “Series Introduction: Neurodegeneration: What is it and where are we?,” *Journal of Clinical Investigation*, vol. 111, no. 1, pp. 3–10, Jan. 2003, doi: 10.1172/jci17522.
- [4] D. J. Selkoe and J. Hardy, “The amyloid hypothesis of Alzheimer’s disease at 25 years,” *EMBO Mol. Med.*, vol. 8, no. 6, pp. 595–608, 2016, doi: 10.15252/emmm.201606210.
- [5] S. Gauthier, P. Rosa-Neto, J. A. Morais, and C. Webster, “World Alzheimer Report 2021: Journey through the diagnosis of dementia,” *Alzheimer’s disease International*, vol. 2022, p. 30, 2021.
- [6] H. Zetterberg and K. Blennow, “From cerebrospinal fluid to blood: the third wave of fluid biomarkers for Alzheimer’s disease,” *Journal of Alzheimer’s Disease*, vol. 64, no. s1, pp. S271–S279, 2018, doi: doi.org/10.3233/jad-179926.
- [7] J. Keener and J. Sneyd, *Mathematical physiology: II: Systems physiology*. Springer, 2009.
- [8] J. T. Jarrett and P. T. Lansbury Jr, “Seeding ‘one-dimensional crystallization’ of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie?,” *Cell*, vol. 73, no. 6, pp. 1055–1058, 1993, doi: 10.1016/0092-8674(93)90635-4.
- [9] A. Raj and F. Powell, “Models of network spread and network degeneration in brain disorders,” *Biol. Psychiatry Cogn. Neurosci. Neuroimaging*, vol. 3, no. 9, pp. 788–797, 2018, doi: 10.1016/j.bpsc.2018.07.012.

- [10] M. I. Falcon *et al.*, “The virtual brain: modeling biological correlates of recovery after chronic stroke,” *Front. Neurol.*, vol. 6, p. 228, 2015, doi: 10.3389/fneur.2015.00228.
- [11] A. Gelman, “How Bayesian analysis cracked the red-state, blue-state problem,” *Statistical science*, pp. 26–35, 2014, doi: 10.48550/arXiv.1405.4687.
- [12] R. M. Neal, “MCMC using Hamiltonian dynamics,” *Handbook of markov chain monte carlo*, vol. 2, no. 11, p. 2, 2011, doi: 10.48550/arXiv.1206.1901.
- [13] C. Anand, P. D. Maia, J. Torok, C. Mezas, and A. Raj, “The effects of microglia on tauopathy progression can be quantified using Nexopathy in silico (Nex is) models,” *Sci. Rep.*, vol. 12, no. 1, p. 21170, 2022, doi: 10.1038/s41598-022-25131-3.
- [14] J. Weickenmeier, “Exploring the multiphysics of the brain during development, aging, and in neurological diseases,” *Brain Multiphys.*, vol. 4, p. 100068, 2023, doi: 10.1016/j.brain.2023.100068.
- [15] C. Soto and L. D. Estrada, “Protein misfolding and neurodegeneration,” *Arch. Neurol.*, vol. 65, no. 2, pp. 184–189, 2008, doi: 10.1001/archneurol.2007.56.
- [16] M. T. Heneka *et al.*, “Neuroinflammation in Alzheimer’s disease,” *Lancet Neurol.*, vol. 14, no. 4, pp. 388–405, 2015, doi: 10.1016/S1474-4422(15)70016-5.
- [17] G. S. Bloom, “Amyloid- β and tau: the trigger and bullet in Alzheimer disease pathogenesis,” *JAMA Neurol.*, vol. 71, no. 4, pp. 505–508, 2014, doi: 10.1001/jamaneurol.2013.5847.
- [18] H. Braak and E. Braak, “Neuropathological staging of Alzheimer-related changes,” *Acta Neuropathol.*, vol. 82, no. 4, pp. 239–259, 1991, doi: 10.1007/bf00308809.
- [19] C. R. Jack *et al.*, “Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers,” *Lancet Neurol.*, vol. 12, no. 2, pp. 207–216, 2013, doi: 10.1016/S1474-4422(12)70291-0.

- [20] A. Raj, A. Kuceyeski, and M. Weiner, “A network diffusion model of disease progression in dementia,” *Neuron*, vol. 73, no. 6, pp. 1204–1215, 2012, doi: 10.1016/j.neuron.2011.12.040.
- [21] B. De Strooper and E. Karran, “The cellular phase of Alzheimer’s disease,” *Cell*, vol. 164, no. 4, pp. 603–615, 2016, doi: 10.1016/j.cell.2015.12.056.
- [22] K. C. N. K. Kwong, P. R. Mehta, G. Shukla, and A. R. Mehta, “COVID-19, SARS and MERS: a neurological perspective,” *Journal of Clinical Neuroscience*, vol. 77, p. 13, 2020, doi: 10.1016/j.jocn.2020.04.124.
- [23] C. A. Lane, J. Hardy, and J. M. Schott, “Alzheimer’s disease,” *Eur. J. Neurol.*, vol. 25, no. 1, pp. 59–70, 2018, doi: 10.1111/ene.13439.
- [24] J. A. Hardy and G. A. Higgins, “Alzheimer’s disease: the amyloid cascade hypothesis,” *Science (1979).*, vol. 256, no. 5054, pp. 184–185, 1992, doi: 10.1126/science.1566067.
- [25] G. P. Morris, I. A. Clark, and B. Vissel, “Questions concerning the role of amyloid- β in the definition, aetiology and diagnosis of Alzheimer’s disease,” *Acta Neuropathol.*, vol. 136, no. 5, pp. 663–689, 2018, doi: 10.1007/s00401-018-1918-8.
- [26] G. I. Hallinan, M. Vargas-Caballero, J. West, and K. Deinhardt, “Tau misfolding efficiently propagates between individual intact hippocampal neurons,” *Journal of Neuroscience*, vol. 39, no. 48, pp. 9623–9632, 2019, doi: 10.1523/jneurosci.1590-19.2019.
- [27] J. Masel, V. A. A. Jansen, and M. A. Nowak, “Quantifying the kinetic parameters of prion replication,” *Biophys. Chem.*, vol. 77, no. 2–3, pp. 139–152, 1999, doi: 10.1016/s0301-4622(99)00016-2.
- [28] M. L. Greer, L. Pujo-Menjouet, and G. F. Webb, “A mathematical analysis of the dynamics of prion proliferation,” *J. Theor. Biol.*, vol. 242, no. 3, pp. 598–606, 2006, doi: 10.1016/j.jtbi.2006.04.010.

- [29] J. D. Murray, “Reaction diffusion, chemotaxis, and nonlocal mechanisms,” in *Mathematical biology: I. An introduction*, Springer, 2002, pp. 395–417. doi: 10.1007/978-0-387-22437-4_11.
- [30] R. J. Hyndman and G. Athanasopoulos, *Forecasting: principles and practice*. OTexts, 2018.
- [31] L. R. Squire, “Memory systems of the brain: a brief history and current perspective,” *Neurobiol. Learn. Mem.*, vol. 82, no. 3, pp. 171–177, 2004, doi: 10.1016/j.nlm.2004.06.005.
- [32] S. Fornari, A. Schäfer, M. Jucker, A. Goriely, and E. Kuhl, “Prion-like spreading of Alzheimer’s disease within the brain’s connectome,” *J. R. Soc. Interface*, vol. 16, no. 159, Oct. 2019, doi: 10.1098/rsif.2019.0356.
- [33] J. A. McNab *et al.*, “The Human Connectome Project and beyond: initial applications of 300 mT/m gradients,” *Neuroimage*, vol. 80, pp. 234–245, 2013, doi: 10.1016/j.neuroimage.2013.05.074.
- [34] Alzheimer’s Disease Neuroimaging Initiative, “ADNI PET Data.”. Online; accessed [2025-05-16], 2023. Data available from the Alzheimer’s Disease Neuroimaging Initiative.